Literature DB >> 16534538

[Productivity costs of rheumatoid arthritis in Germany. Cost composition and prediction of main cost components].

S Merkesdal1, J L Huelsemann, T Mittendorf, S Zeh, H Zeidler, J Ruof.   

Abstract

OBJECTIVE: Identification of predictors for the productivity cost components: (1) sick leave, and (2) work disability in gainfully employed and (3) impaired household productivity in unemployed patients with rheumatoid arthritis (RA) from the societal perspective.
METHODS: Investigation of productivity costs was linked to a multicenter, randomized, controlled trial evaluating the effectiveness of clinical quality management in 338 patients with RA. The productivity losses were assessed according to the German Guidelines on Health Economic Evaluation. By means of multivariate logistic regression analyses, predictors of sick leave, work disability (employed patients, n=96), and for days confined to bed in unemployed patient (n=242) were determined.
RESULTS: Mean annual costs of 970 EUR arose per person taking into consideration all patients (453 EUR sick leave, 63 EUR work disability, 454 EUR impaired productivity of unemployed patients). Disease activity, disease severity, and impaired physical function were global predictors for all of the cost components investigated. Sick leave costs were predicted by prior sick leave periods and the vocational status blue collar worker, work disability costs by sociodemographic variables (marital status, schooling), and the productivity costs of unemployed patients by impaired mental health and impaired physical functions.
CONCLUSIONS: Interventions such as reduction in disease progression and control of disease activity, early vocational rehabilitation measures and vocational retraining in patients at risk of quitting working life, and self-management programs to learn coping strategies might decrease future RA-related productivity costs.

Entities:  

Mesh:

Year:  2006        PMID: 16534538     DOI: 10.1007/s00393-005-0024-1

Source DB:  PubMed          Journal:  Z Rheumatol        ISSN: 0340-1855            Impact factor:   1.372


  15 in total

Review 1.  [Health economics research in the area of chronic polyarthritis].

Authors:  S Merkesdal; J Ruof; T Mittendorf; W Mau; H Zeidler
Journal:  Z Rheumatol       Date:  2002-02       Impact factor: 1.372

2.  Predicting the short term direct medical costs incurred by patients with rheumatoid arthritis.

Authors:  A E Clarke; C Levinton; L Joseph; J Penrod; H Zowall; J T Sibley; S A Grover; J M Esdaile
Journal:  J Rheumatol       Date:  1999-05       Impact factor: 4.666

3.  Direct and indirect costs associated with the onset of seropositive rheumatoid arthritis. Western Consortium of Practicing Rheumatologists.

Authors:  K Newhall-Perry; N J Law; B Ramos; M Sterz; W K Wong; K J Bulpitt; G Park; M Lee; P Clements; H E Paulus
Journal:  J Rheumatol       Date:  2000-05       Impact factor: 4.666

4.  A multicenter cost-of-illness study on rheumatoid arthritis in Italy.

Authors:  G Leardini; F Salaffi; R Montanelli; S Gerzeli; B Canesi
Journal:  Clin Exp Rheumatol       Date:  2002 Jul-Aug       Impact factor: 4.473

5.  Direct medical costs and their predictors in patients with rheumatoid arthritis: a three-year study of 7,527 patients.

Authors:  Kaleb Michaud; Jodi Messer; Hyon K Choi; Frederick Wolfe
Journal:  Arthritis Rheum       Date:  2003-10

6.  Determinants of direct costs in Dutch rheumatoid arthritis patients.

Authors:  S M M Verstappen; H Verkleij; J W J Bijlsma; E Buskens; A A Kruize; A H M Heurkens; M J Van Der Veen; J W G Jacobs
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

7.  Costs of rheumatoid arthritis in Germany: a micro-costing approach based on healthcare payer's data sources.

Authors:  J Ruof; J L Hülsemann; T Mittendorf; S Handelmann; J M von der Schulenburg; H Zeidler; S Merkesdal
Journal:  Ann Rheum Dis       Date:  2003-06       Impact factor: 19.103

8.  Costs of rheumatoid arthritis in France: a multicenter study of 1109 patients managed by hospital-based rheumatologists.

Authors:  Francis Guillemin; Stephanie Durieux; Jean-Pierre Daurès; Antoine Lafuma; Alain Saraux; Jean Sibilia; Pierre Bourgeois; Jacques Sany
Journal:  J Rheumatol       Date:  2004-07       Impact factor: 4.666

9.  Indirect medical costs in the first 3 years of rheumatoid arthritis: comparison of current methodological approaches.

Authors:  Sonja Merkesdal; Jörg Ruof; Thomas Mittendorf; Henning Zeidler; Wilfried Mau
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2002-08       Impact factor: 2.217

10.  The use of the disease activity score in the analysis of clinical trials in rheumatoid arthritis.

Authors:  H A Fuchs
Journal:  J Rheumatol       Date:  1993-11       Impact factor: 4.666

View more
  3 in total

1.  [Health economic aspects of a stratified medicine for rheumatoid arthritis].

Authors:  M Frank; T Mittendorf
Journal:  Z Rheumatol       Date:  2013-02       Impact factor: 1.372

2.  Quality of life and occupational disability in endocrine orbitopathy.

Authors:  Katharina A Ponto; Susanne Pitz; Norbert Pfeiffer; Gerhard Hommel; Matthias M Weber; George J Kahaly
Journal:  Dtsch Arztebl Int       Date:  2009-04-24       Impact factor: 5.594

Review 3.  Newer biological agents in rheumatoid arthritis: impact on health-related quality of life and productivity.

Authors:  Vibeke Strand; Jasvinder A Singh
Journal:  Drugs       Date:  2010       Impact factor: 9.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.